Request Demo
Recent blog posts
Latest Hotspot
8 min read
Urothelial Cancer Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Urothelial Cancer clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Head and Neck Squamous Cell Carcinoma Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Head and Neck Squamous Cell Carcinoma clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and…
Latest Hotspot
8 min read
Cervical Cancer Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Cervical Cancer clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Visepegenatide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Visepegenatide: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Endometrial Cancer Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Endometrial Cancer clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Ovarian Cancer Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Ovarian Cancer clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Glioblastoma Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Glioblastoma clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Advanced Melanoma Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Advanced Melanoma clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Anagliptin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Anagliptin/Empagliflozin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Clear Cell Renal Cell Carcinoma Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Clear Cell Renal Cell Carcinoma clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development…
Latest Hotspot
8 min read
Metastatic Castration-Resistant Prostate Cancer Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Metastatic Castration-Resistant Prostate Cancer clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and…
Latest Hotspot
8 min read
Biliary Tract Cancer Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Biliary Tract Cancer clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.